(Q39427936)

11 September 2017

title

Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis (English)

1 reference

Mycobacterium tuberculosis

11 September 2017

main subject

1 reference

Mycobacterium bovis

1 reference

based on heuristic

inferred from title

author

Pere-Joan Cardona i Iglesias

14

1 reference

11 September 2017

Nuria Andreu

9

0 references

Cristina Vilaplana

object named as

Cristina Vilaplana

4

0 references

Peter Sander

object named as

Peter Sander

1

0 references

Erik C Böttger

16

object named as

Erik C Böttger

1 reference

11 September 2017

Simon Clark

2

1 reference

11 September 2017

Agnese Petrera

3

1 reference

11 September 2017

Michael Meuli

5

1 reference

11 September 2017

Petra Selchow

6

1 reference

11 September 2017

Andrea Zelmer

7

1 reference

11 September 2017

Deepa Mohanan

8

1 reference

11 September 2017

Emma Rayner

10

1 reference

11 September 2017

Michael Dal Molin

11

1 reference

11 September 2017

Gregory J Bancroft

12

1 reference

11 September 2017

Pål Johansen

13

1 reference

11 September 2017

Ann Williams

15

1 reference

11 September 2017

language of work or name

English

0 references

publication date

2 February 2015

1 reference

11 September 2017

1 reference

11 September 2017

volume

33

1 reference

11 September 2017

issue

11

1 reference

11 September 2017

page(s)

1353-1359

1 reference

Prospects for Tuberculosis Elimination

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Genome plasticity of BCG and impact on vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Novel vaccination strategies against tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Vaccines against tuberculosis: where are we and where do we need to go?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Recombinant live vaccine candidates against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Crystal Structure of Mycobacterium tuberculosis Zinc-dependent Metalloprotease-1 (Zmp1), a Metalloprotease Involved in Pathogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Functional characterization of the Mycobacterium tuberculosis zinc metallopeptidase Zmp1 and identification of potential substrates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Mycobacterium tuberculosis prevents inflammasome activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

BCG Δzmp1 vaccine induces enhanced antigen specific immune responses in cattle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Adjuvants induce distinct immunological phenotypes in a bovine tuberculosis vaccine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Expression of the Bacillus subtilis sacB gene confers sucrose sensitivity on mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

The physiology and pathogenicity of Mycobacterium tuberculosis grown under controlled conditions in a defined medium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Survival of mycobacterial species in aerosols generated from artificial saliva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Survival of Mycobacterium tuberculosis during experimental aerosolization and implications for aerosol challenge models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

In search of a new paradigm for protective immunity to TB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

A synthetic mammalian gene circuit reveals antituberculosis compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

The second Geneva Consensus: Recommendations for novel live TB vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Divergence of immunologic and protective responses of different BCG strains in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Has BCG attenuated to impotence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Assessment of vaccine testing at three laboratories using the guinea pig model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.058

10.1016/J.VACCINE.2015.01.058

7 January 2021

Identifiers

DOI

1 reference

11 September 2017

1 reference